Clinical trial · Interventional
Uterine Fibroid Embolization- Long Term Follow up and Technical Perspectives
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this prospective non-randomised study is to examine whether two different microspheres (Bead-Block and Embosphere) are equally effective in the treatment of the uterine fibroid controlled with contrast-enhanced MR examination. Quantitative MR imaging, including dominant fibroid T1, T2 and contrast enhancement characteristics before intervention and 3 months after interventions will be analysed as a potential predictor of volumetric response after embolization. Another purpose is to determine long-term follow-up in all patient treated in a period from 2001-2011 in OUH analysed retrospectively.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Arterial Embolization | — | UNRESOLVED | — |
| Uterine Fibroids | Uterine Corpus Leiomyoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| embolizations | Procedure | — | UNRESOLVED |
| embolizations ,uterine fibroid | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- embolizations, uterine fibroid
- description
- embolization interventions with microspheres
- interventionNames
- Procedure: embolizations ,uterine fibroid
- Procedure: embolizations
Primary outcomes (1)
- measure
- clinical effect
- timeFrame
- one year
- description
- Primary goal is to achieve release of symptoms after intervention and it would be compared between the two techniques
Secondary outcomes (1)
- measure
- reinterventions rate
- timeFrame
- one year
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 52 Years
Show eligibility criteria text
Inclusion Criteria: * symptomatic uterus fibroma Exclusion Criteria: * pelvic infection (cystitis, oophoritis, salpingitis, abscess, urethritis) * gravidity * uterus malignancy * big subserosal fibroma with stalk diameter of \<2 cm * menopausal women * don,t want to be included into the study * concomitant adenomyosis
References
Publications (0)
Data not yet available